BioCryst Pharmaceuticals is discontinuing its internal discovery programs and closing its Birmingham research facility by the end of 2026 to prioritize external innovation for developing rare disease treatments. This strategic shift aims to accelerate pipeline growth more efficiently by leveraging partnerships and external capabilities. The company continues advancing two key clinical programs: navenibart for hereditary angioedema, with Phase 3 enrollment complete, and BCX17725 for Netherton syndrome, with data expected by year-end 2026. BioCryst also resolved a manufacturing delay for ORLADEYO oral pellets, now expected to be available in early August 2026, and lowered its 2026 non-GAAP operating expense guidance to $420-$440 million while reaffirming revenue targets.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
